red blood cells

 

The Joint Commission’s new National Patient Safety Goal (NPSG) for anticoagulation therapy will become effective July 1, 2019. The intention of the standards is to reduce the risk of medication-related adverse events and applies to all Joint Commission-accredited hospitals, Critical Access Hospitals (CAHs) and nursing care centers as well as medical centers accredited through the ambulatory healthcare program.

A rise in Adverse Drug Events (ADEs) associated with direct oral anticoagulants has prompted the development of six new and the reorganization of two preexisting elements of performance. The standards emphasize the need for accredited facilities to implement and document evidence-based protocols and guidelines for the management of anticoagulant therapy, including the reversal of anticoagulation to reduce the likelihood of patient harm.

Patient Education
The sixth element addresses patient and family education to ensure awareness of the risk for bleeding and/or clotting that can lead to severe adverse drug events. Education recommendations include medication adherence, dose and schedule compliance, drug and food interactions, and the need for follow-up appointments and ongoing laboratory tests as well as how foods and other medicines can adversely interact with anticoagulants.

Click here to review all eight elements and associated rationale.

“By following the Joint Commission Standards, medication errors can be prevented, patient safety increased and overall better healthcare outcomes achieved.” ~Becky Gillgannon, BSN, RN, Great Plains QIN Quality Improvement Project Manager.

The Great Plains QIN partners with providers, pharmacists and stakeholders in our region to reduce and monitor ADE rates, including those related to anticoagulants. Visit our website to access tools, resources and educational events relating to medication safety.